- Home
- ENB vs SNY Comparison
ENB vs SNY Comparison
Compare ENB & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENB | SNY |
|---|---|---|
| Founded | 1949 | 1994 |
| Country | Canada | France |
| Employees | 14800 | 74846 |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5B | 104.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ENB | SNY |
|---|---|---|
| Price | $55.10 | $42.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $65.00 | $58.00 |
| AVG Volume (30 Days) | 3.0M | ★ 4.1M |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | ★ 5.13% | 3.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.49 |
| Revenue Next Year | $3.22 | $6.10 |
| P/E Ratio | $21.67 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.59 | $40.89 |
| 52 Week High | $58.45 | $52.68 |
Technical Indicators
Market Signals| Indicator | ENB | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 48.94 |
| Support Level | $54.14 | $42.64 |
| Resistance Level | $56.71 | $43.48 |
| Average True Range (ATR) | 1.04 | 0.82 |
| MACD | -0.10 | 0.11 |
| Stochastic Oscillator | 58.49 | 74.68 |
Price Performance
Historical ComparisonAbout ENB Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the US and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also operates regulated natural gas utilities in the US and Canada, including Canada's largest natural gas distribution company. The firm has a small renewable energy portfolio primarily focused on onshore and offshore wind projects.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.